biostudies-literatureZhou BShanghai Municipal Health Commission Health Industry Clinical Research SpecialShanghai Municipal Science and Technology CommissionClinical Key Disease Diagnosis and Treatment Technology Project of Suzhou Municipal Health CommissionNaval Medical University and Eastern Hepatobiliary Surgery Hospitaloyaf439https://www.ebi.ac.uk/biostudies/studies/S-EPMC12854084biostudies-literatureUnknown31(2)<h4>Background</h4>Sintilimab plus bevacizumab (Sin + Bev) is recommended as a first-line treatment for hepatocellular carcinoma (HCC) with portal vein tumor thrombus (PVTT); however, its efficacy remains limited. This study aimed to assess the efficacy and safety of stereotactic body radiotherapy (SBRT) combined with Sin + Bev for HCC with PVTT.<h4>Patients and methods</h4>This retrospective study included 69 HCC patients with PVTT treated at two centers in China from August 2021 to December 2022. Patients received either SBRT + Sin + Bev (n = 31) or Sin + Bev alone (n = 38). Primary endpoints were overall survival (OS) and progression-free survival (PFS). Secondary endpoints included objective response rate (ORR) and treatment-related adverse events (TRAEs).<h4>Results</h4>Baseline charaThe oncologistReal-world outcomes of stereotactic body radiotherapy plus sintilimab and bevacizumab for hepatocellular carcinoma with portal vein tumor thrombus.PMC1285408420244Y0165LCZX2022352022QN098/2022GZR00722Y11908900Jiang YCheng SLu XLu YZhou BLu CMa ZWei XCheng XWang LfalseReal-world outcomes of stereotactic body radiotherapy plus sintilimab and bevacizumab for hepatocellular carcinoma with portal vein tumor thrombus.<h4>Background</h4>Sintilimab plus bevacizumab (Sin + Bev) is recommended as a first-line treatment for hepatocellular carcinoma (HCC) with portal vein tumor thrombus (PVTT); however, its efficacy remains limited. This study aimed to assess the efficacy and safety of stereotactic body radiotherapy (SBRT) combined with Sin + Bev for HCC with PVTT.<h4>Patients and methods</h4>This retrospective study included 69 HCC patients with PVTT treated at two centers in China from August 2021 to December 2022. Patients received either SBRT + Sin + Bev (n = 31) or Sin + Bev alone (n = 38). Primary endpoints were overall survival (OS) and progression-free survival (PFS). Secondary endpoints included objective response rate (ORR) and treatment-related adverse events (TRAEs).<h4>Results</h4>Baseline chara2026-01-01T00:00:00Z2026 Jan2026-06-16T03:19:18.754Z2026-06-16T03:09:59.599ZS-EPMC128540844149500110.1093/oncolo/oyaf439